[Federal Register Volume 68, Number 169 (Tuesday, September 2, 2003)]
[Notices]
[Page 52224]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-22329]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to section 1301.33(a) of title 21 of the Code of Federal 
Regulations (CFR), this is notice that on June 2, 2003, Bristol Myers 
Squibb Pharma Company, 1000 Stewart Avenue, Garden City, New York 
11530, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of 
Oxycodone (9143), a basic class of controlled substance listed in 
Schedule II.
    The firm plans to manufacture the controlled substances to make 
finished products.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: Federal Register Representative, 
Office of Chief Counsel (CCD) and must be filed no later than November 
3, 2003.

    Dated: August 19, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control.
[FR Doc. 03-22329 Filed 8-29-03; 8:45 am]
BILLING CODE 4410-09-M